On the stock market since 2019, it operates in the world of health and science. It has 69 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
There is $743.1M in the vault; even if every debt were paid off, $706.6M would remain.
A loss of $252.1M against $0 in annual sales.
Over the last 12 months, executives reported 269 sells against just 77 buys. Not an alarm bell by itself, but a number worth watching.
The stock trades 11% above the average analyst price target.
On our five-subject report card, AKRO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: AKRO is a high-risk stock — not yet profitable, and its future rides on its product catching on.